Ischemic brain infarcts, white matter hyperintensities, and cognitive impairment are increased in patients with Atrial Fibrillation
- PMID: 41593217
- DOI: 10.1038/s43856-026-01389-w
Ischemic brain infarcts, white matter hyperintensities, and cognitive impairment are increased in patients with Atrial Fibrillation
Abstract
Background: The interrelationships between atrial fibrillation (AF), brain lesions and cognitive function are poorly understood. We aimed to investigate the relationship of AF with brain lesions and cognition.
Methods: We enrolled 1,480 patients with and 959 without AF in a multicenter prospective study (Swiss-AF; NCT02105844). We assessed brain structure, and cognition using the Montreal Cognitive Assessment (MoCA). Brain magnetic resonance imaging (MRI) was performed to assess large non-cortical and cortical infarcts (LNCCI), small non-cortical infarcts (SNCI), white matter hyperintensities (WMH), and microbleeds. Using causal mediation analyses, we investigated the direct (lesion-independent) and indirect (lesion-mediated) effects of AF on cognition.
Results: Mean age in AF patients is 75.0 vs. 74.2 years in no-AF patients, 28.6% vs. 36.9% are female, and comorbidities are comparable. The prevalence of MRI-detected brain infarcts (LNCCI and/or SNCI) is 40.1% in AF patients vs. 24.0% in no-AF patients, adjusted OR (95% CI): 1.78 (1.30; 2.44), p = 0.0003. WMH (Fazekas ≥2) are more prevalent in AF patients (59.2% vs 44.4%), adjusted OR (95% CI): 2.03 (1.50; 2.77), p = 4.6e-06. The mean MoCA score is 25.3 in AF patients and 26.4 in no-AF patients. In mediation analysis, the total effect of AF on cognition is -1.05 MoCA points, decomposed into a direct effect of -0.99 and an indirect, lesion-mediated, effect of -0.06 points.
Conclusions: The prevalence of ischemic brain infarcts and WMH is higher in patients with AF than without AF despite comparable comorbidities. AF is associated with lower cognitive function, primarily through a direct effect rather than mediated by brain lesions.
Plain language summary
Atrial fibrillation is a common heart rhythm disorder in which there is an irregular heartbeat. It has been associated with damage to the brain and reduced cognitive function, which is the mental processes involved in thinking, learning, and processing information. However, the relationship is poorly understood. We assessed brain structure and cognitive function in people with similar characteristics that either had or did not have atrial fibrillation. We found that people with atrial fibrillation had more brain damage visible by brain imaging and lower cognitive function, compared to people without atrial fibrillation. The brain damage seen did not seem to be the main cause of the lower cognitive function. The main driver of lower cognitive function was most probably the arrhythmia itself.
© 2026. The Author(s).
Conflict of interest statement
Competing interests: Philipp Krisai (PK) reports speaker fees from BMS/Pfizer and Biosense Webster, and research grants from the Swiss National Science Foundation, Swiss Heart Foundation, Foundation for Cardiovascular Research Basel, Machaon Foundation. Michael Kühne (MK) reports grants from Bayer, grants from BMS, grants from Boston Scientific, grants from Daiichi Sankyo, grants from Pfizer, personal fees from Abbott, personal fees from Boston Scientific, personal fees from Daiichi Sankyo, and royalties from Springer (ECG book). Stefan Osswald (SO) reports grants from Swiss National Science Foundation, Swiss Heart Foundation, Foundation for Cardiovascular Research Basel. Felix Mahfoud (FM) has been supported by Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Forschungsgemeinschaft (SFB TRR219, Project-ID 322900939), and Deutsche Herzstiftung. In the past 24 months, Saarland University has received scientific support from Ablative Solutions, Medtronic and ReCor Medical. Until May 2024, FM has received speaker honoraria/consulting fees from Ablative Solutions, Amgen, Astra-Zeneca, Bayer, Boehringer Ingelheim, Inari, Medtronic, Merck, ReCor Medical, Servier, and Terumo. Matthias Schwenkglenks (MS) reports grants from Swiss National Science Foundation, for the conduct of the study; grants from Amgen, grants from MSD, grants from Novartis, grants from Pfizer, grants from Roche, grants and personal fees from BMS and personal fees from Sandoz, all outside the submitted work. David Conen (DC) reports speaker fees from Servier, consulting fees from Trimedics. Giorgio Moschovitis (GM) has received advisory board or speaker’s fees from Astra Zeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Gebro Pharma, Novartis and Vifor, all outside of the submitted work. All other authors declare no competing interest.
References
-
- Lloyd-Jones, D. M. et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 110, 1042–1046 (2004).
-
- Krijthe, B. P. et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur. Heart J. 34, 2746–2751 (2013).
-
- Prince, M. et al. The global prevalence of dementia: A systematic review and metaanalysis. Alzheimers Dement 9, 63–75 (2013).
-
- Kalantarian, S., Stern, T. A., Mansour, M. & Ruskin, J. N. Cognitive impairment associated with atrial fibrillation: a meta-analysis. Ann. Intern. Med. 158, 338–346 (2013).
-
- Conen, D. et al. Relationships of Overt and Silent Brain Lesions With Cognitive Function in Patients With Atrial Fibrillation. J. Am. Coll. Cardiol. 73, 989–999 (2019).
LinkOut - more resources
Full Text Sources